Long Term Efficacy and Safety of Orlistat for Type 1 Hyperlipoproteinemia

Recruiting now · Phase 2 · Has a placebo group

Conditions studied: Type 1 Hyperlipoprotenemia

In brief

Type I hyperlipoproteinemia (T1HLP, also known as familial chylomicronemia syndrome or FCS) is a rare diseasewhere the blood triglycerides (fats) are very high. It is caused by lack of certain enzymes and proteins in the bodythat are important in disposing circulating fats from blood. Treatment of T1HLP patients who have very high levels of blood fats (≥ 1,000 mg/dL) is challenging as conventional triglyceride-lowering medications, such as fibrates and fishoil, are ineffective. The purpose of this trial is to study the long-term efficacy and safety of orlistat for reducing blood triglyceride levels in patients with T1HLP.

Key facts

Study ID: NCT05816343
Run by: University of Texas Southwestern Medical Center
People needed: 28
Starts: 2024-01-26
Expected to finish: 2029-05-30
Last updated by the study team: 2026-07-21

Who can join

Age: 8 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Age ≥ 8 years
Type I hyperlipoproteinemia confirmed by bi-allelic disease-causing variants in any one of the T1HLP genes (LPL, APOC2, APOA5, LMF1, GPIHBP1, or GCKR).
Subjects with digenic inheritance with heterozygous disease-causing variants in two different T1HLP genes.
Subjects who have a fasting TG greater than or equal to 750 mg/dL at the end of run-in period of 8 weeks will be eligible for randomization.
Subjects who do not have confirmed genetic mutation for Type 1 hyperlipoproteinemia but have a fasting TG greater than or equal to 750 mg/dL at the end of run-in period of 8 weeks will be eligible for randomization.
Well controlled diabetes mellitus with hemoglobin A1c < 8%
Off orlistat for a period of 2 months
Patients on Olezarsen and Plozasiran (APOC3 antisense oligonucleotide) can enroll if on the drug for more than 3 months
Following methods of contraception for males and females of childbearing age will be employed Males: Being in this research may damage your sperm, which could cause harm to a child that you may father while on this study. If you take part in this study and are sexually active, you must agree to use a medically-acceptable form of birth control. Medically-acceptable forms of birth control include: (1) surgical sterilization (vasectomy), or (2) a condom used with a spermicide (a substance that kills sperm).
Females: If you are part of this study while pregnant or breast-feeding an infant, it is possible that you may expose the unborn child or infant to risks. For that reason, pregnant and breast-feeding females cannot participate in the study. If you can become pregnant, a blood or urine pregnancy test will be done, and it must be negative before you participate in this study. If you take part in this study and you are sexually active, you and any person that you have sex with must use medically-acceptable birth control (contraceptives) during the study. Medically-acceptable birth control (contraceptives) includes: (1) surgical sterilization (such as hysterectomy or "tubes tied"), (2) approved hormonal contraceptives (such as birth control pills, patch or ring; Depo-Provera, Implanon), (3) barrier methods (such as condom or diaphragm) used with a spermicide (a substance that kills sperm), or (4) an intrauterine device (IUD). If you do become pregnant during this study, you must tell the researchers immediately.

You may not qualify if…

Secondary hypertriglyceridemia due to diabetes, renal disease, alcoholism and drug therapy such as estrogens and estrogen analogues, steroids, HIV-1 protease inhibitors, retinoic acid derivatives, interferons, or lasparaginase.
On lomitapide or participating in clinical trial of volanesorsen.
On cyclosporine
Having serum TSH outside of the normal range if on levothyroxine supplementation.
Use of levothyroxine to suppress TSH in individuals with thyroid cancer.
Pregnant or lactating women
Significant liver disease (elevated transaminases > 2 times upper limit of normal)
Alcohol abuse (> 7 drinks or 84 g per week for women and > 14 drinks or 168 g per week for men)
Severe anemia (hematocrit < 24%)
Illicit drug use (cocaine, marijuana, LSD, etc.)
Major surgery in the past three months
Congestive heart failure
Serum creatinine greater than 2.5 mg/dL
Cancer within the past five years
Gastrointestinal surgery in the past
Current therapy with anti-coagulants, digoxin and anti-arrhythmics
Chronic malabsorption syndromes
Cholestasis
Acute illnesses such as acute pancreatitis in the last 8 weeks
Previous history of renal calcium oxalate stones

Where it is running

UT southwestern Medical Center — Dallas, Texas, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.